OverviewSuggest Edit

Luye Pharma Group (绿叶制药) is a pharmaceutical company that develops, manufactures, and sells medications. It offers a range of products covering central nervous system, oncology, and other therapeutic areas. In addition, the company focuses on technologies such as microspheres, liposomes, and transdermal drug delivery systems to develop biological antibodies, cell and gene therapies.
TypePublic
Founded1994
HQCN
Websiteluye.cn

Latest Updates

Employees (est.) (Dec 2018)4,417
Share Price (Apr 2021)$4.7(-1%)
Cybersecurity ratingBMore

Luye Pharma Office Locations

Luye Pharma has an office in
Show all (1)

Luye Pharma Financials and Metrics

Luye Pharma Revenue

Market capitalization (30-Apr-2021)

16.7b

Closing stock price (30-Apr-2021)

4.7
Luye Pharma's current market capitalization is $16.7 b.
Show all financial metrics

Luye Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Luye Pharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Luye Pharma Online and Social Media Presence

Embed Graph

Luye Pharma News and Updates

Liposome Drug Delivery Market Top Leading Players, Share, Future Trends | Luye Pharma Group, Acrotech Biopharma, Pacira Biosciences

The liposome drug delivery market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019. The market is estimated to grow at a CAGR of 8.8% from 2020 to 2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

Luye Pharma Signs Two Agreements in Latin America, Global Business System for Seroquel Continues to Grow Rapidly

SHANGHAI, Sept. 11, 2020 /PRNewswire/ -- Luye Pharma Group recently signed two agreements with partners in Latin America, boosting further development of the central nervous system (CNS) drugs Seroquel® (quetiapine fumarate, immediate release, IR) and Seroquel XR® (extended release...

La demande d'autorisation de mise sur le marché de Rivalif®, patch transdermique multijours à base de rivastigmine de Luye Pharma, est en cours d'examen par les autorités compétentes de l'UE

MISBACH, Allemagne, 21 mai 2020 /PRNewswire/ -- Luye Pharma Group a annoncé aujourd'hui que la demande d'autorisation de mise sur le marché (AMM) au sein du territoire européen de son patch transdermique multijours à base de rivastigmine (nom de marque : Rivalif®, code produit : LY30410),...

Luye Pharma Frequently Asked Questions

  • When was Luye Pharma founded?

    Luye Pharma was founded in 1994.

  • How many employees does Luye Pharma have?

    Luye Pharma has 4,417 employees.

  • Who are Luye Pharma competitors?

    Competitors of Luye Pharma include Hisamitsu Pharmaceutical, OncoArendi Therapeutics and Dragonfly.

  • Where are Luye Pharma offices?

    Luye Pharma has an office in.

  • How many offices does Luye Pharma have?

    Luye Pharma has 1 office.